Download Image
    
Share
  
Post
P2Et for COVID-19
1 study with 91 patients
Hospital Icon Control
Hospital Icon P2Et Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 P2Et studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -114% Mortality -114% Hospitalization 23% RCTs -114% Late -114% FavorsP2Et Favorscontrol
P2Et is an oral phytomedicine, an extract from Caesalpinia spinosa, with potential anti-inflammatory and antiviral effects. Recent:
Urueña.
Sep 8
2022
 Urueña et al., Frontiers in Medicine, doi:10.3389/fmed.2022.991873 Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)
24% lower ICU admission (p=0.76) and 23% shorter hospitalization (p=0.12). RCT 91 hospitalized COVID-19 patients in Colombia showing no significant differences in clinical outcomes with P2Et treatment. P2Et treatment was associated with reduced pro-inflammatory cytokines (G-CSF, IL-5, IL-18) and increased NK cel..